-
Featured Authors
Archive
- May 2013 (2)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
BIO Travels to Brazil to Support the Ecosystem of Innovation
Government policies that support innovation are critical as the biotechnology industry seeks to develop innovative healthcare, agricultural, industrial and environmental biotechnology products and provide them to people all around the world. Innovation requires not only scientific research and commercial expertise, but also supportive and dynamic governments that help facilitate long-term growth of the industry. Brazil has recognized the value of innovation in maintaining a robust, diversified economy that can compete in the 21st century, and declared Read More >
BIO Technology Transfer Symposium: Funding that First $2 Million
With creative funding schemes picking up steam and nontraditional funders taking an interest in biotech, what can universities and start-ups expect in their right first-round financing structure? At the BIO Technology Transfer Symposium, a panel examined various funding sources as well as the factors that influence investment decisions and the ins and outs of early stage financing deals. William Tucker, executive director, Innovation Alliances and Services, University of California Office of the President, moderated a Read More >
Technology Transfer: Promoting Public-Private Collaborations for Innovation
BIO President and CEO Jim Greenwood penned an op-ed for the September issue of BioPharm International on the importance of technology transfer from academia to industry, as encouraged by the Bayh-Dole Act of 1980. The Bayh-Dole Act, which permits and encourages industry to partner with research universities to turn federally-funded basic research into new and valuable products, is a critical factor in driving America’s innovation economy. Because of this legislation, the U.S. leads the world Read More >
Finding Value in Early Stage Collaborations at the BIO Technology Transfer Symposium
The BIO Technology Transfer Symposium dissects recent academia-industry collaborations and evaluates the value in early stage biotechnology investments. The event occurs in San Francisco on October 8th ahead of the BIO Investor Forum and provides a unique opportunity for bringing academia, industry, and the investment community together. This year’s event is headlined by Tom Thornton from the Cleveland Clinic, a leading academic medical center. The first panel highlights the collaboration between Duke Translational Research Institute Read More >
Strong IP Protection is Critical Component of Trade Agreement
The next round of discussion on the Trans-Pacific Partnership (TPP) began yesterday in nearby Leesburg, VA. The TPP currently includes eleven countries (Australia, Brunei, Canada, Chile, Malaysia, Mexico, New Zealand, Peru, Singapore, U.S. and Vietnam) and other countries in the region, such as Japan and Korea, may join in the future. The TPP will set an important precedent for global trade rules. It is described by the U.S. Trade Representative as “an ambitious, 21st-century … Read More >
